ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

Jing Wu; Christine Bryla; Yu-Ting Su; Ewa Grajkowska; Ann McCoy; Lisa Boris; Ramya Antony; Nancy Garren; Christine Siegel; Christine Cordova; Orwa Aboud; Elizabeth Vera; Tracy Lawhon; Marta Penas-Prado; Brett Theeler; Tito Mendoza; Terri Armstrong; Ying Yuan; Mark Gilbert

doi:10.1093/NEUONC/NOZ175.104

ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

Jing Wu, Christine Bryla, Yu-Ting Su, Ewa Grajkowska, Ann McCoy, Lisa Boris, Ramya Antony, Nancy Garren, Christine Siegel, Christine Cordova, Orwa Aboud, Elizabeth Vera, Tracy Lawhon, Marta Penas-Prado, Brett Theeler, Tito Mendoza, Terri Armstrong, Ying Yuan, Mark Gilbert

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Neuro-oncology
Volume	21
DOIs	https://doi.org/10.1093/NEUONC/NOZ175.104
State	Published - Nov 11 2019
Externally published	Yes

Disciplines

Oncology
Internal Medicine
Medicine and Health Sciences

Access to Document

10.1093/NEUONC/NOZ175.104License: Unspecified

Cite this

Wu, J., Bryla, C., Su, Y.-T., Grajkowska, E., McCoy, A., Boris, L., Antony, R., Garren, N., Siegel, C., Cordova, C., Aboud, O., Vera, E., Lawhon, T., Penas-Prado, M., Theeler, B., Mendoza, T., Armstrong, T., Yuan, Y., & Gilbert, M. (2019). ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS. Neuro-oncology, 21. https://doi.org/10.1093/NEUONC/NOZ175.104

Wu, J, Bryla, C, Su, Y-T, Grajkowska, E, McCoy, A, Boris, L, Antony, R, Garren, N, Siegel, C, Cordova, C, Aboud, O, Vera, E, Lawhon, T, Penas-Prado, M, Theeler, B, Mendoza, T, Armstrong, T, Yuan, Y & Gilbert, M 2019, 'ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS', Neuro-oncology, vol. 21. https://doi.org/10.1093/NEUONC/NOZ175.104

@article{69fbf9fdfebf4933885b3144947b7af3,

title = "ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS",

author = "Jing Wu and Christine Bryla and Yu-Ting Su and Ewa Grajkowska and Ann McCoy and Lisa Boris and Ramya Antony and Nancy Garren and Christine Siegel and Christine Cordova and Orwa Aboud and Elizabeth Vera and Tracy Lawhon and Marta Penas-Prado and Brett Theeler and Tito Mendoza and Terri Armstrong and Ying Yuan and Mark Gilbert",

note = "AbstractBACKGROUND. Therapies targeting multiple survival pathways are desirable for high-grade gliomas. TG02 (Zotiraciclib), a CDK9 inhibitor, regulates transc",

year = "2019",

month = nov,

day = "11",

doi = "10.1093/NEUONC/NOZ175.104",

language = "American English",

volume = "21",

journal = "Neuro-oncology",

}

TY - JOUR

T1 - ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

AU - Wu, Jing

AU - Bryla, Christine

AU - Su, Yu-Ting

AU - Grajkowska, Ewa

AU - McCoy, Ann

AU - Boris, Lisa

AU - Antony, Ramya

AU - Garren, Nancy

AU - Siegel, Christine

AU - Cordova, Christine

AU - Aboud, Orwa

AU - Vera, Elizabeth

AU - Lawhon, Tracy

AU - Penas-Prado, Marta

AU - Theeler, Brett

AU - Mendoza, Tito

AU - Armstrong, Terri

AU - Yuan, Ying

AU - Gilbert, Mark

N1 - AbstractBACKGROUND. Therapies targeting multiple survival pathways are desirable for high-grade gliomas. TG02 (Zotiraciclib), a CDK9 inhibitor, regulates transc

PY - 2019/11/11

Y1 - 2019/11/11

UR - http://academic.oup.com/neuro-oncology/article-pdf/21/Supplement_6/vi27/30632703/noz175.104.pdf

U2 - 10.1093/NEUONC/NOZ175.104

DO - 10.1093/NEUONC/NOZ175.104

M3 - Article

VL - 21

JO - Neuro-oncology

JF - Neuro-oncology

ER -

ACTR-62. PHASE I TRIAL OF TG02 PLUS DOSE-DENSE OR METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE ASTROCYTOMA IN ADULTS

Disciplines

Access to Document

Other files and links

Cite this